公开(公告)号：US20110002943A1

公开(公告)日：2011-01-06

申请号：US12743903

申请日：2008-11-28

Applicant: Heikki Hyöty ,  Sisko Tauriainen ,  Sami Oikarinen ,  Maarit Oikarinen ,  Markku Mäki ,  Katri Kaukinen ,  Teemu Honkanen ,  Immo Rantala

Inventor： Heikki Hyöty ,  Sisko Tauriainen ,  Sami Oikarinen ,  Maarit Oikarinen ,  Markku Mäki ,  Katri Kaukinen ,  Teemu Honkanen ,  Immo Rantala

IPC: A61K39/42 ,  C12Q1/70 ,  A61K39/12 ,  A61K35/76 ,  C12N7/00 ,  C07K16/08 ,  A61P3/00 ,  A61P37/04 ,  A61P31/12

CPC classification number: G01N33/56983 ,  A61K39/12 ,  A61K39/125 ,  C12N2770/32311 ,  C12N2770/32332 ,  C12N2770/32334 ,  G01N2800/02 ,  G01N2800/04 ,  G01N2800/06

Abstract: The invention is based on the finding that enterovirus is present in body samples of patients with celiac disease. The invention opens up the possibility for using enteroviruses in diagnosing, preventing, treating and monitoring the treatment of celiac-related diseases. The invention relates to a method for diagnosing, treating and monitoring the treatment of a celiac-related disease. The invention also relates to the use of enteroviruses or components or antibodies thereof for producing a vaccine, and the use of anti-enterovirus compositions for preparing a pharmaceutical against said disease.

Abstract translation: 本发明是基于肠道病毒存在于乳糜泻患者的身体样品中的发现。 本发明开辟了使用肠道病毒诊断，预防，治疗和监测乳糜泻相关疾病治疗的可能性。 本发明涉及诊断，治疗和监测乳糜泻相关疾病的治疗方法。 本发明还涉及肠道病毒或其组分或其抗体用于生产疫苗的用途，以及使用抗肠道病毒组合物制备抗所述疾病的药物。

公开(公告)号：US20100034848A1

公开(公告)日：2010-02-11

申请号：US12523328

申请日：2008-01-31

Applicant: Hanna Viskari ,  Mikael Knip ,  Tapio Seiskari ,  Heikki Hyöty ,  Laura Kummola ,  Anita Kondrashova

Inventor： Hanna Viskari ,  Mikael Knip ,  Tapio Seiskari ,  Heikki Hyöty ,  Laura Kummola ,  Anita Kondrashova

IPC: A61K39/00

CPC classification number: A61K39/35 ,  A61K35/76 ,  C12N2770/32311 ,  C12N2770/32332

Abstract: The present invention relates to prevention and treatment of allergic sensitization and diseases associated therewith by treatment with an enterovirus vaccine, wherein the enterovirus does not contain an exogenous nucleic acid sequence that is integrated into the viral genome and that encodes an allergen that induces said allergic sensitization.

Abstract translation: 本发明涉及通过肠道病毒疫苗的治疗来预防和治疗过敏性致敏及其相关疾病，其中肠道病毒不含有整合到病毒基因组中并编码诱导所述过敏致敏的变应原的外源性核酸序列 。

公开(公告)号：US08182805B2

公开(公告)日：2012-05-22

申请号：US12523328

申请日：2008-01-31

Applicant: Hanna Viskari ,  Mikael Knip ,  Tapio Seiskari ,  Heikki Hyöty ,  Laura Kummola ,  Anita Kondrashova

Inventor： Hanna Viskari ,  Mikael Knip ,  Tapio Seiskari ,  Heikki Hyöty ,  Laura Kummola ,  Anita Kondrashova

IPC: A61K39/12 ,  A61K39/35

CPC classification number: A61K39/35 ,  A61K35/76 ,  C12N2770/32311 ,  C12N2770/32332

Abstract: The present invention relates to prevention and treatment of allergic sensitization and diseases associated therewith by treatment with an enterovirus vaccine, wherein the enterovirus does not contain an exogenous nucleic acid sequence that is integrated into the viral genome and that encodes an allergen that induces said allergic sensitization.

Abstract translation: 本发明涉及通过肠道病毒疫苗的治疗来预防和治疗过敏性致敏及其相关疾病，其中肠道病毒不含有整合到病毒基因组中并编码诱导所述过敏致敏的变应原的外源性核酸序列 。

公开(公告)号：US07972592B2

公开(公告)日：2011-07-05

申请号：US11471937

申请日：2006-06-21

Applicant: Heikki Hyöty ,  Mikael Knip

Inventor： Heikki Hyöty ,  Mikael Knip

IPC: A61K35/00 ,  A61K48/00

CPC classification number: A61K39/125 ,  A61K39/12 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/57 ,  A61K2039/58 ,  C12N2770/32334 ,  C12N2770/32634 ,  Y02A50/466

Abstract: Live virus vaccines comprise attenuated viruses, while other vaccines comprise killed viruses or parts thereof. It has now been found that the immune response induced by oral poliovirus vaccine (OPV), which is a live vaccine, is cross-reactive with non-polio enteroviruses. OPV is therefore useful in the prevention of non-polio enterovirus diseases, especially Type 1 diabetes mellitus (IDDM). OPV is also useful in combination with killed/subunit non-polio enterovirus vaccines, whereby it prevents harmful side-effects of the killed/subunit vaccine by shifting the immune response from a harmful Th2-type response to a Th1 type response.

Abstract translation: 活病毒疫苗包括减毒病毒，而其他疫苗包括杀死的病毒或其部分。 现在已经发现，作为活疫苗的口服脊髓灰质炎病毒疫苗（OPV）诱导的免疫应答与非脊髓灰质炎肠道病毒交叉反应。 因此，OPV可用于预防非脊髓灰质炎肠道病毒疾病，特别是1型糖尿病（IDDM）。 OPV还与杀死/亚单位非脊髓灰质炎肠炎病毒疫苗组合使用，从而通过将免疫应答从有害Th2型反应转移到Th1型反应来防止杀死/亚单位疫苗的有害副作用。

公开(公告)号：US07090855B1

公开(公告)日：2006-08-15

申请号：US10009016

申请日：2000-03-17

Applicant: Heikki Hyöty ,  Mikael Knip

Inventor： Heikki Hyöty ,  Mikael Knip

IPC: A61K39/13 ,  A61K39/295 ,  A61K39/125

CPC classification number: A61K39/125 ,  A61K39/12 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/57 ,  A61K2039/58 ,  C12N2770/32334 ,  C12N2770/32634 ,  Y02A50/466

Abstract: Live virus vaccines comprise attenuated viruses, while other vaccines comprise killed viruses or parts thereof. It has now been found that the immune response induced by oral poliovirus vaccine (OPV), which is a live vaccine, is cross-reactive with non-polio enteroviruses. OPV is therefore useful in the prevention of non-polio enterovirus diseases, especially Type 1 diabetes mellitus (IDDM). OPV is also useful in combination with killed/subunit non-polio enterovirus vaccines, whereby it prevents harmful side-effects of the killed/subunit vaccine by shifting the immune response from a harmful Th2-type response to a Th1 type response.

Abstract translation: 活病毒疫苗包括减毒病毒，而其他疫苗包括杀死的病毒或其部分。 现在已经发现，作为活疫苗的口服脊髓灰质炎病毒疫苗（OPV）诱导的免疫应答与非脊髓灰质炎肠道病毒交叉反应。 因此，OPV可用于预防非脊髓灰质炎肠道病毒疾病，特别是1型糖尿病（IDDM）。 OPV还与杀死/亚单位非脊髓灰质炎肠炎病毒疫苗组合使用，从而通过将免疫应答从有害Th2型反应转移到Th1型反应来防止杀死/亚单位疫苗的有害副作用。